Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

Msd R&d Co., Ltd.

Vanessa L Rada

Ian M Bell

Brendan M Crowley

John M Sanders

Brian T Campbell

Kenneth J Leavitt

Deodial Guy Guiadeen

Melissa S Egbertson

William D Shipe

Linda M Suen

Yimin Qian

Mark T Bilodeau

Yuntae Kim

John A McCauley

Dong-Ming Shen

Thomas J Greshock

Andrew John Harvey

Jianming Bao

Michael Man-Chu Lo

Robert S Meissner

Ling Tong

Shawn J Stachel

Deping Wang

Michael T Rudd

Robert D Mazzola, Jr

XiaoXia Qian

Harry R Chobanian

David M Tellers

Xiaolei Gao

Timothy J Henderson

Richard Berger

Shimin Xu

Joseph Leslie Duffy

Christopher Joseph Sinz

John J Acton, Iii

Zhaoyang Meng

James J Mulhearn

Hemaka Anthony Rajapakse

Fengqi Zhang

Chunsing Li

Scott T Harrison

Bart Harper

Oleg B Selyutin

Belinda C Huff

Edward J Brnardic

Meng Yang

Jonathan E Wilson

Boyoung Kim

Ming Wang

Zack Zhiqiang Guo

Heather E Stevenson

Jeffrey W Schubert

Timothy A Cernak

James I Fells

Jonathan T Kern

Celina V Zerbinatti

Dong Ming Shen

Christopher J Sinz

Zack Zhi Qiang Guo

Joseph L Duffy

Deodial G Guiadeen

John J Iii Acton

Robert D Mazzola

The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor

The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I). 

Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula (I) that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation. 

Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors

Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors

In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R, R, R, R, R, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation 

Allosteric modulators of nicotinic acetylcholine receptors

Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof. 

Pyrimidone carboxamide compounds as PDE2 inhibitors

Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein 'A' is S&#x2014;; &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;O&#x2014; or NR&#x2014;, wherein Rac is H, or Calkyl and Rthrough Rare defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease. 

Leucine-rich repeat kinase enzyme activity

Growing community of inventors

Hatfield, PA, United States of America

Vanessa L Rada